Advancing treatment with interferon beta-1b (Betaferon®/Betaseron®) in the next decade: Thinking beyond the standard dose

Journal of Neurology, Supplement

Volumn 250, Issue 4, 2003, Pages 15-20

  Cook, Stuart D ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Biological markers; High dose; High frequency; Interferon beta 1b; Multiple sclerosis; Relapsing remitting

Indexed keywords

BETA 2 MICROGLOBULIN; BETA INTERFERON; BETA1A INTERFERON; BIOLOGICAL MARKER; GLATIRAMER; IBUPROFEN; INTERFERON BETA SERINE; INTERLEUKIN 10; NEOPTERIN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO;

ASTHENIA; BRAIN INJURY; CENTRAL NERVOUS SYSTEM; CHILL; CLINICAL TRIAL; CONFERENCE PAPER; CYTOKINE PRODUCTION; DISABILITY; DISEASE ACTIVITY; DISEASE COURSE; DRUG APPROVAL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG POTENCY; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; EVIDENCE BASED MEDICINE; FEVER; FLU LIKE SYNDROME; FREQUENCY ANALYSIS; HEADACHE; HEPATITIS C; HUMAN; INCIDENCE; INFLAMMATION; INJECTION PAIN; INJECTION SITE; LABORATORY TEST; LOW DRUG DOSE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; PRIORITY JOURNAL; RELAPSE; REMISSION; SIDE EFFECT; SKIN MANIFESTATION; STANDARD; SYMPTOM; TREATMENT OUTCOME;

CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS;

EID: 0346962897     PISSN: 09391517     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (18)

1. Bayas A, Rieckmann P (2000) Managing the adverse effects of interferon-beta therapy in multiple sclerosis. Drug Saf 22:149-159
2. Chiron Corp (2003) Data on file
3. Clanet M, Radue EW, Kappos L, Hartung HP, Hohlfeld R, Sandberg-Wollheim M, Kooijmans-Coutinho MF, Tsao EC, Sandrock AW; European IFN-beta-1a (Avonex) Dose-Comparsion Study Investigators (2002) A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology 59:1507-1517
4. Durelli L, Oggero A, Verdun E, Barbero P, Pipieri A, Isoardo G, Ricci A, Clerico M, Bradac G, Bergamasco B, Bergui M (2001) Interferon-beta dose and efficacy: the OPTIMS study. Neurol Sci 22:201-203
5. Durelli L, Verdun E, Barbero P, Bergui M, Versino E, Ghezzi A, Montanari E, Zaffaroni M (2002) Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 359:1453-1460
6. Hurwitz BJ, Arnason BG, Bigley GK, Coyle PK, Goodin DS, Jeffery DR, Kaba S, Thrower B, Kirzinger SS, Lynch S, Mandler R, Mikol D, Rammohan KW, Safer R, Sriram S, Abdul-Ahad A, Byrnes W, Wash M, Boateng F, Bogumil T, Jakobs P (2003) Safety and tolerability of 500 mg versus 250 mg of interferon beta-1b - first stage of the BEYOND (Betaseron®/Betaferon® Efficacy Yielding Outcomes of a New Dose) program. Mult Scler 9(Suppl 1):S40. Poster 182
7. IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:655-661
8. IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group (1995) Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45:1277-1285
9. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, Simonian NA, Slasor PJ, Sandrock AW (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 343:898-904
10. Knobler RL, Greenstein JI, Johnson KP, Lublin FD, Panitch HS, Conway K, Grant-Gorsen SV, Muldoon J, Marcus SG, Wallenberg JC et al. (1993) Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up. J Interferon Res 13:333-340
11. Panitch H, Goodin DS, Francis G, Chang P, Coyle PK, O'Connor P, Monaghan E, Li D, Weinshenker B (2002) Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology 59:1496-1506
12. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352: 1498-1504
13. Rice GP, Ebers GC, Lublin FD, Knobler RL (1999) Ibuprofen treatment versus gradual introduction of interferon beta-1b in patients with MS. Neurology 52:1893-1895
14. Rothuizen LE, Buclin T, Spertini F, Trinchard I, Munafo A, Buchwalder PA, Ythier A, Biollaz J (1999) Influence of interferon beta-1a dose frequency on PBMC cytokine secretion and biological effect markers. J Neuroimmunol 99:131-141
15. Sturzebecher S, Maibauer R, Heuner A, Beckmann K, Aufdembrinke B (1999) Pharmacodynamic comparison of single doses of IFN-beta1a and IFN-beta1b in healthy volunteers. J Interferon Cytokine Res 19:1257-1264
16. Tornatore C, Bartlett D (2002) Tolerability of interferon beta-1b (Betaferon/Betaseron) can be significantly improved using both interferon-free needle and automated infection techniques. J Neurol 249:I/205
17. Walther EU, Hohlfeld R (1999) Multiple sclerosis: side effects of interferon beta therapy and their management. Neurology 53:1622-1627
18. Williams GJ, Witt PL (1998) Comparative study of the pharmacodynamic and pharmacologic effects of Betaseron and AVONEX. J Interferon Cytokine Res 18:967-975